HCC Master Calculator: A Research Tool for Comparative Staging Analysis
Enter patient data once. Compare Child-Pugh, ALBI, MELD-Na, BCLC, HKLC, and Milan criteria side-by-side. Built for clinical trial researchers who need to understand staging system concordance and discordance.
Why Staging System Comparison Matters in HCC Research?
Background: Why Hepatocellular carcinoma (HCC) has no universally adopted staging system?
Unlike breast cancer (AJCC TNM) or lung cancer (TNM stage groups), HCC staging must simultaneously account for:
- Tumor burden
- Liver function
- Patient performance status
As a result, multiple staging systems are used in parallel across regions and studies:
- BCLC (Barcelona Clinic Liver Cancer) – European / Western standard
- HKLC (Hong Kong Liver Cancer) – Asian-developed, more aggressive surgical criteria
- CNLC (China Liver Cancer) – Mainland China standard
- CLIP / JIS – Prognostic scoring systems used in some regions and legacy datasets
- Child-Pugh / ALBI – Liver function assessment
- MELD-Na – Transplant allocation and short-term mortality risk
The Research Problem
Question 1: Which staging system should we use?
Question: “Should we stratify patients by BCLC stage or HKLC stage?”
Why this matters: The same patient may be classified as “intermediate stage” by BCLC but considered resection-eligible under HKLC. This directly affects eligibility, treatment assignment, and expected outcomes.
Answer with Master Calculator: Compute both BCLC and HKLC simultaneously and quantify how many patients fall into concordant vs discordant categories before finalizing stratification rules.
Question 2: How do we compare trials that used different systems?
Question: “How do we compare results from a Japanese trial using JIS with a European trial using BCLC?”
Why this matters: Apparent differences in survival or treatment efficacy may reflect differences in staging definitions rather than true biological or therapeutic effects.
Answer with Master Calculator: Reclassify patients from both datasets into a common set of staging systems (e.g., BCLC + JIS + Child-Pugh/ALBI) to enable fair cross-trial comparison.
Question 3: Who are the hidden surgical candidates?
Question: “What percentage of our BCLC Stage B patients would be considered surgical candidates under HKLC criteria?”
Why this matters: These patients often have better outcomes and may be preferentially selected for surgery in some regions, introducing treatment selection bias in observational studies and trials.
Answer with Master Calculator: Instantly identify and quantify BCLC–HKLC discordant subgroups using the same patient-level data.
In summary:
The HCC Master Calculator was built to answer these questions by computing all major staging and liver function systems simultaneously from a single data entry, enabling transparent, reproducible research and clinically meaningful trial design.
📋 Article Outline
Research Applications of the HCC Master Calculator
1. Clinical Trial Eligibility Mapping
Use Case: Cross-Trial Comparison
Scenario: You're designing a Phase III trial for TACE + immunotherapy combination.
Challenge: European trials enroll "BCLC Stage B," but Asian trials use "HKLC Stage IIb + IIIa."
Solution: Use the Master Calculator to determine what percentage of your target population would be eligible under both criteria, enabling direct comparison of trial results.
2. Comparative Effectiveness Research
Use Case: Real-World Evidence (RWE) Concordance Check
Scenario: You're analyzing a registry cohort labeled as “BCLC Stage B” to compare outcomes across centers or regions.
Challenge: “BCLC B” is a heterogeneous bucket. Some patients may be “HKLC Stage IIa” (often considered surgical candidates in HKLC frameworks), while others are “HKLC IIb/IIIa” (more aligned with TACE-focused pathways). This hidden mix can distort outcome comparisons.
Solution: Batch-calculate BCLC + HKLC for the entire cohort and quantify discordance (e.g., % of BCLC B that maps to HKLC IIa vs IIb vs IIIa). Then run sensitivity analyses stratified by concordant vs discordant subgroups.
3. Patient Stratification for Biomarker Studies
Use Case: Biomarker Subgroup Stratification by Liver Reserve
Scenario: You're testing whether a biomarker predicts response or survival differently across levels of liver function in a treated HCC cohort.
Challenge: Liver function assessment varies by system:
- Child-Pugh uses subjective variables (ascites, encephalopathy)
- ALBI uses objective labs only (albumin, bilirubin)
- MELD-Na prioritizes short-term mortality/urgency (transplant context)
If you stratify using only one system, you may misclassify liver reserve or miss clinically meaningful subgroups.
Solution: Use the Master Calculator to classify every patient simultaneously by Child-Pugh, ALBI, and MELD-Na, then pre-specify biomarker analyses in (1) each system separately and (2) concordant vs discordant liver-function subgroups.
4. Research Question
Use Case: Discordant Subgroup Hypothesis Testing
Scenario: You want to test whether biomarker performance changes when liver function is classified differently by subjective vs objective systems.
Challenge: A patient can be “Child-Pugh B” yet “ALBI Grade 2” (or vice versa), creating discordant subgroups that may behave differently in treatment response and survival analyses.
Solution: Use the Master Calculator to rapidly identify these discordant groups and test: “Does the biomarker predict response differently in Child-Pugh B vs ALBI Grade 2 patients?” This allows you to evaluate whether your biomarker is truly biology-driven or partially confounded by liver reserve classification.
What the Master Calculator Computes
Liver Function Assessment (3 Systems)
Child-Pugh Score
ALBI Grade
MELD-Na Score
Cancer Staging Systems (3 Primary + 2 Prognostic)
BCLC Staging (2022 Update)
HKLC Staging
Milan Criteria
Additional Systems: CLIP Score, JIS Score (calculated when applicable)
Data Architecture & Input Requirements
Single Entry Point, Intelligent Routing
The calculator uses a unified input form that captures all variables needed across systems:
Laboratory Values (5 inputs):
- Total Bilirubin (µmol/L)
- Albumin (g/L)
- INR
- Serum Creatinine (µmol/L)
- Serum Sodium (mmol/L)
Clinical Assessment (3 inputs):
- Ascites (None / Slight / Moderate-Severe)
- Encephalopathy (None / Grade 1-2 / Grade 3-4)
- ECOG Performance Status (0 / 1 / 2 / >2)
Imaging Findings (4 inputs):
- Number of Tumors (1 / 2-3 / >3)
- Maximum Tumor Diameter (cm)
- Macrovascular Invasion (Yes/No)
- Extrahepatic Metastasis (Yes/No)
Additional (1 input):
- Dialysis Status (for MELD calculation)
Data Dependencies Between Systems
Critical for Research: Understanding these dependencies is essential for missing data imputation strategies in retrospective analyses.
Staging System Concordance Analysis
Known Patterns of Agreement and Disagreement
High Concordance Scenarios:
✓ Early Stage HCC
✓ Advanced/Terminal Disease
Discordance Hot Zones:
⚠️ Intermediate Stage: BCLC Stage B
This is where the systems diverge most significantly.
Research Implication: Patient Selection Bias
Observation: A trial enrolling "BCLC Stage B" patients in Hong Kong may have different outcomes than a European trial with the same eligibility criteria.
Mechanism: Asian centers applying HKLC logic may preferentially select BCLC Stage B patients for resection if they meet HKLC Stage IIa criteria, leaving a more advanced TACE-only population.
Solution: Report BOTH BCLC and HKLC stage distribution in trial publications to enable proper cross-trial comparison.
Case Example: BCLC vs. HKLC Discordance
Hypothetical Patient Profile
Demographics & Labs:
- 62-year-old male, HBV cirrhosis
- Albumin 38 g/L, Bilirubin 18 µmol/L, INR 1.1
- No ascites, no encephalopathy
- ECOG PS 0
Imaging:
- Single 7 cm mass, right lobe
- No vascular invasion
- No metastasis
Staging System Outputs
Liver Function Scores
Staging Systems
⚠️ Staging Discordance Detected
BCLC: Stage B → TACE recommended (intermediate stage, palliative intent)
HKLC: Stage IIa → Resection preferred (potentially curative)
Research Questions This Case Raises
Clinical Trial Design Use Cases
Use Case 1: Multi-Regional Trial Harmonization
Scenario: Global Phase III trial, sites in Europe, USA, Japan, Hong Kong, and China
Challenge: Each region uses a different primary staging system in clinical practice
Solution with Master Calculator:
Use Case 2: Retrospective Cohort Analysis
Scenario: Analyzing 10-year institutional database to identify predictors of long-term survival after TACE
Data Available: Labs (albumin, bilirubin, INR, creatinine), imaging (tumor characteristics), clinical notes (ascites, encephalopathy)
Research Question: "Does ALBI Grade outperform Child-Pugh for predicting post-TACE survival?"
Workflow:
Use Case 3: Patient Stratification for Biomarker Studies
Scenario: Testing a ctDNA-based recurrence prediction biomarker after HCC resection
Biological Hypothesis: Biomarker performance depends on underlying liver function (cirrhosis severity affects ctDNA shedding)
Study Design Using Master Calculator:
Frequently Asked Questions
Q:How do I validate the calculator's outputs for research use?
- BCLC 2022: Reig et al., J Hepatol 2022;76(3):681-693
- HKLC: Yau et al., Gastroenterology 2014;146(7):1691-1700
- ALBI: Johnson et al., J Clin Oncol 2015;33(6):550-558
- MELD 3.0: Kim et al., JAMA 2021;326(20):2017-2026
Validation Method: Spot-check the first 10-20 cases from your dataset by manually calculating scores using the original papers. The calculator includes formula breakdowns for transparency.
Q:Can I export data for statistical analysis?
- CSV Data Polisher: Clean and prepare your data for statistical analysis
- Treatment Survival Analysis Tool: Generate Kaplan-Meier curves and evaluate treatment efficacy
Complete Research Workflow: Our integrated platform allows you to calculate staging scores, export patient data, and perform survival analysis all within the same application - streamlining your clinical research workflow.
Q:How should I report staging in publications when systems disagree?
Primary Staging: Use the system specified in your protocol (usually BCLC for international trials)
Secondary Reporting: Include a supplementary table showing stage distribution by alternative systems
Discordance Analysis: Report the percentage of patients with stage discordance and test for outcome differences in concordant vs. discordant subgroups
Example: "Among 150 BCLC Stage B patients, 45 (30%) met HKLC Stage IIa criteria (resection-eligible). Median OS was 28 months in concordant BCLC-B/HKLC-IIb patients vs. 42 months in discordant BCLC-B/HKLC-IIa patients (p=0.03)."
Q:What about missing data? How does the calculator handle it?
- Child-Pugh: Requires all 5 inputs. Returns N/A if any are missing.
- BCLC/HKLC: Depend on Child-Pugh. If Child-Pugh is N/A, these also return N/A.
- MELD-Na: If Sodium is missing, returns Base MELD with explicit notation.
Research Implication: This strict approach prevents silent data quality issues. For retrospective studies, you'll know exactly which cases lack complete staging data and can perform sensitivity analyses.
Q:Is this appropriate for clinical decision-making or just research?
The calculator is designed to help researchers understand how different staging systems classify the same patient. It highlights areas of concordance and discordance.
Important Note: Clinical treatment decisions should be made by multidisciplinary teams considering institutional expertise, patient values, and local practice patterns. The calculator provides classification, not clinical recommendations.
- Protocol development for clinical trials
- Retrospective cohort analysis
- Cross-trial comparison studies
- Teaching staging system differences to trainees/fellows
- Quality improvement projects assessing staging consistency
Try the HCC Master Calculator
🔬 Research Tool for Staging Comparison
Enter patient data once and compare staging across BCLC, HKLC, CLIP, Child-Pugh, ALBI, MELD-Na, and Milan criteria simultaneously.
Key Features for Researchers
Side-by-Side Comparison
Transparent Calculations
Evidence-Based Algorithms
Individual Calculators Also Available
If you need focused analysis of a single system:
We welcome feedback from clinical trial researchers and epidemiologists. Your insights help improve the tool for the entire oncology research community.